Bristol-Myers Squibb, a leader and innovator in the fight against cardiovascular disease for decades, remains committed to discovering and developing new medicines in this critical therapeutic area.
Cardiovascular disease represents the leading cause of death in the developed world. Many important advances have been made in the treatment of cardiovascular diseases and that progress must continue. Taking a focused approach, we concentrate on conditions with ongoing and significant unmet medical needs. These include arrhythmia, atrial fibrillation, atherosclerosis, heart failure and thrombosis.
Our researchers are working on a number of innovative programs in these disease areas with the goal of identifying safer, more targeted and more effective therapies. For example, a series of compounds in clinical development are being studied to treat atrial fibrillation, the most common type of abnormal heart rhythm, at the cellular level by regulating specific ion channels that play a key role in maintaining normal heart rhythm. An atherosclerosis program is exploring a novel vascular biology approach that seeks to address the disease at the vessel wall to potentially stabilize and decrease the plaque that can accumulate and become dangerous over time.
The relationship between heart disease and diabetes is another important area of our research. Since diabetes increases the risk of heart disease and stroke, we seek to develop diabetes drugs that are safe in terms of cardiovascular risk and even potentially able to show a cardiovascular benefit.
In addition to programs for investigational compounds, approved medicines also typically undergo continued clinical development as researchers look into potential new indications and formulations that could benefit patients.
Bristol-Myers Squibb has a long history of leadership in the treatment of cardiovascular disease. The first ACE inhibitor, a major discovery in the treatment of high blood pressure and heart failure, was developed here nearly four decades ago and continues to be prescribed today. That commitment continues in the discovery and development of new medicines and therapies that may one day give hope to cardiovascular patients worldwide.